Table 2 Association of polypharmacy with incident frailty
From: Effect modification of polypharmacy on incident frailty by chronic kidney disease in older adults
Total | Number of participants with incident frailty (%) | Crude Model OR (95% CI) | Adjusted Model* OR (95% CI) | |
|---|---|---|---|---|
Regular Prescription Polypharmacy | ||||
No Polypharmacy | 389 | 46 (11.8) | Reference | Reference |
Polypharmacy | 229 | 51 (22.3) | 2.14 (1.38–3.31) | 1.96 (1.20–3.19) |
Hyperpolypharmacy | 18 | 5 (27.8) | 2.87 (0.98–8.41) | 2.87 (0.85–9.69) |
Active Substance Polypharmacy | ||||
No Polypharmacy | 367 | 44 (12.0) | Reference | Reference |
Polypharmacy | 238 | 49 (20.6) | 1.90 (1.22–2.97) | 1.73 (1.06–2.81) |
Hyperpolypharmacy | 31 | 9 (29.0) | 3.00 (1.30–6.94) | 2.86 (1.11–7.39) |
Regular Polypharmacy | ||||
No Polypharmacy | 319 | 39 (12.2) | Reference | Reference |
Polypharmacy | 277 | 48 (17.3) | 1.51 (0.95–2.38) | 1.32 (0.79–2.21) |
Hyperpolypharmacy | 40 | 15 (37.5) | 4.31 (2.09–8.87) | 4.08 (1.70–9.81) |
Regular and On-Demand Polypharmacy | ||||
No Polypharmacy | 261 | 29 (11.1) | Reference | Reference |
Polypharmacy | 302 | 52 (17.2) | 1.66 (1.02–2.71) | 1.56 (0.91–2.67) |
Hyperpolypharmacy | 73 | 21 (28.8) | 3.23 (1.71–6.11) | 3.01 (1.43–6.37) |
All Polypharmacy | ||||
No Polypharmacy | 207 | 22 (10.6) | Reference | Reference |
Polypharmacy | 309 | 48 (15.5) | 1.55 (0.90–2.65) | 1.45 (0.81–2.59) |
Hyperpolypharmacy | 120 | 32 (26.7) | 3.06 (1.68–5.57) | 3.03 (1.52–6.05) |